Aethlon Medical (NASDAQ:AEMD) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright decreased their price target on shares of Aethlon Medical from $23.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, March 4th.

Aethlon Medical Price Performance

Shares of NASDAQ AEMD opened at $1.70 on Thursday. The company has a 50 day simple moving average of $1.72 and a 200-day simple moving average of $1.82. The company has a market capitalization of $4.45 million, a P/E ratio of -0.34 and a beta of 1.88. Aethlon Medical has a 1 year low of $1.40 and a 1 year high of $7.20.

Aethlon Medical (NASDAQ:AEMD) last posted its earnings results on Wednesday, February 14th. The medical equipment provider reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.14). As a group, research analysts expect that Aethlon Medical will post -4.98 EPS for the current year.

Institutional Investors Weigh In On Aethlon Medical

Several institutional investors have recently modified their holdings of AEMD. Renaissance Technologies LLC lifted its position in Aethlon Medical by 61.4% in the fourth quarter. Renaissance Technologies LLC now owns 100,600 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 38,264 shares during the last quarter. HRT Financial LP acquired a new position in Aethlon Medical during the fourth quarter worth about $28,000. Two Sigma Investments LP purchased a new stake in shares of Aethlon Medical in the third quarter valued at about $32,000. Jane Street Group LLC lifted its holdings in shares of Aethlon Medical by 895.7% in the fourth quarter. Jane Street Group LLC now owns 140,245 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 126,160 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of Aethlon Medical in the third quarter valued at about $72,000. 1.99% of the stock is owned by hedge funds and other institutional investors.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.